Yazar "Utku, Semra" seçeneğine göre listele

Listeleniyor 1 - 4 / 4
  • Küçük Resim
    Öğe
    Cytotoxicity and DNA interactions of some platinum(II) complexes with substituted benzimidazole ligands
    (Informa Healthcare, 2012) Ozcelik, Azime Berna; Utku, Semra; Gumus, Fatma; Keskin, Ayten Celebi; Acik, Leyla; Yilmaz, Sukran; Ozgungor, Adeviye
    In the present study, four Pt(II) complexes with 2-ethyl (1)/or benzyl (2)/or p-chlorobenzyl (3)/or 2-phenoxymethyl (4) benzimidazole carrier ligands were evaluated for their in vitro cytotoxic activities against the human HeLa cervix, oestrogen receptor-positive MCF-7 breast, and oestrogen receptor-negative MDA-MB 231 breast cancer cell lines. The plasmid DNA interactions and inhibition of the BamHI restriction enzyme activities of the complexes were also studied. Complex 3 was found to be more active than carboplatin for all examined cell lines and comparable with cisplatin, except for the HeLa cell line.
  • Küçük Resim
    Öğe
    Synthesis, Characterization And Dna Interaction Of Novel Platinum(Ii) Complexes Contaning Substituted Benzimidazole Ligands
    (Editura Acad Romane, 2017) Nzeyimana, Abdoul; Utku, Semra; Acik, Leyla; Keskin, Ayten Celebi
    Eight novel Pt(II) complexes corresponding to the following general formula [PtCl2(L-1-L-4)(2)] (C1 -C4) and [PtI2((L1-L4))(2)] (C5-C8) in which 5(6)-chloro/or-methyl-2-H/or-methylbenzimidazole (L-1-L-4) played the key role as carrier ligands were synthesized and characterized by elemental analysis, IR and H-1 NMR. Considering leaving group functions, the anionic ligand iodido and chloro were utilized with the purpose of studying the interaction between the synthesized complexes and pBR322 plasmid DNA by using cisplatin as positive control throughout the Agarose Gel Electrophoresis method. Therefore, looking after plasmid DNA interacting outcomes, synthesized complexes modified the tertiary structure of pBR322 plasmid DNA, and the results showed that the complex C2 ([PtCl2(L-2)(2)]) was highly active compound regarding to all synthesized complexes.
  • Küçük Resim
    Öğe
    Synthesis, characterization and in vitro cytotoxic activity of platinum(II) oxalato complexes involving 2-substitutedimidazole or 2-substitutedbenzimidazole derivatives as carrier ligands
    (Istanbul Univ, Fac Pharmacy, 2023) Ertuğrul, Emine Merve; Özçelik, Azime Berna; Çerçi, Nebahat Aytuna; Açık, Leyla; Utku, Semra
    Background and Aims: Cisplatin is currently one of the most widely used anticancer drugs in the world. However, its clinical usefulness has frequently been limited by severe side effects, such as nephrotoxicity, ototoxicity and neurotoxicity. Therefore, platinum(II) oxalato complexes with substitute imidazole or benzimidazole carrier ligands were synthesized and their cytotoxic effects were investigated against non-small cell lung cancer (H1299) and human colon adenocarcinoma (CaCo-2), and mouse fibroblast cells lines (L929).Methods: Four platinum(II) complexes, [Pt(L1-L4)2(oxalate)] were synthesized and characterized by FT-IR, 1H NMR and elemental analyses. The MTT method was used to determine the potential antiproliferative effect of synthesized platinum(II) complexes and positive controls.Results: In this study, the cytotoxic activity of platinum(II) complexes against tested cell lines was assessed, with moderate IC50 values. According to IC50 values, Complex 5 with 2-ethylbenzimidazole ligand was found to be the most active complex against H1299 and CaCo-2 cell lines. In general, the compounds are also promising drug candidates for H1299 cell lines with very low activity against the CaCo-2 cell lines.Conclusion: Further modification and development of Complex 4 and 5 derivatives and in vitro cytotoxic activity studies against different cancer cell lines may lead to the emergence of new anticancer agents in the near future.
  • Küçük Resim
    Öğe
    Synthesis, in-vitro cytotoxic activity and DNA interactions of new dicarboxylatoplatinum(II) complexes with 2-hydroxymethylbenzimidazole as carrier ligands
    (Wiley, 2014) Utku, Semra; Ozcelik, Azime Berna; Gumus, Fatma; Yilmaz, Sukran; Arsoy, Taibe; Acik, Leyla; Keskin, Ayten Celebi
    ObjectivesThe aim of this study was to investigate the in-vitro cytotoxic activity of new platinum(II) complexes on the human HeLa (ER-), MCF-7 (ER+) and MDA-MB 231 (ER-) cell lines. Furthermore, we investigated plasmid DNA interactions and inhibition of BamHI and HindIII restriction enzyme activity of the complex 1-4,7. MethodsPlatinum(II) complexes were synthesised from precursor complexes of [PtL2Cl2] and [PtL2I2]. Their cytotoxic activity was tested by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Their plasmid DNA interactions and restriction enzyme activities were also investigated using the agarose gel electrophoresis method. Key findingsThe growth inhibitory effect results showed that the cytotoxicity of complex 2 was found to be the most active complex among the synthesised complexes. ConclusionsThe MTT results showed that complex 2 was found to be cytotoxic equal to cisplatin and higher than carboplatin against the MCF-7 and MDA-MB-231 cell lines. Furthermore, the estrogen or progesterone co-treatment slightly increased the cytotoxicity of complex 2, the cisplatin and carboplatin compared with the complex 2 tested alone in 50m concentration. According to plasmid DNA interaction and the restriction studies, complexes 1-4,7 modified the tertiary structure of pBR322 plasmid DNA, and complexes 2-4 prevented enzyme digestion at high concentrations.